Peptides for Liver health
The peptides people most often research for liver health, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 6
- With human trials
- 4
- FDA approved (any use)
- 3
- TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 38856224Human143Animal15Summarised3FDA approved (Mounjaro, Zepbound)For liver healthOverview
- SemaglutideGLP-1 agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40305708Human305Animal59Summarised2FDA approved (Ozempic, Wegovy, Rybelsus)For liver healthOverview
- Kisspeptin-10GnRH stimulatorAnimal evidence, 2 of 4Cells 2025, PMID 40862768Human0Animal3Summarised3Not FDA approved · research chemicalFor liver healthOverview
- BPC-157Gastric pentadecapeptideAnimal evidence, 2 of 4Life sciences 2022, PMID 36228773Human3Animal22Summarised1PCAC voted 8–6 for 503A (Jul 2026)For liver healthOverview
- RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4Nature medicine 2024, PMID 38858523Human18Animal4Summarised2Investigational · phase 3For liver healthOverview
- TesamorelinGHRH analogHuman RCT evidence, 4 of 4The lancet. HIV 2019, PMID 31611038Human14Animal1Summarised1FDA approved (Egrifta)For liver healthOverview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.What liver disease covers
MedlinePlus describes the liver as the largest organ inside the body, helping digest food, store energy and remove poisons.[7]
MedlinePlus says liver disease sometimes causes no symptoms.[7]
Which peptides have human liver data
PubMed records matching the site's liver search: Tirzepatide 143 human-only and 15 animal-only; Semaglutide 305 human-only and 59 animal-only; Kisspeptin 0 human-only and 3 animal-only; BPC-157 3 human-only and 22 animal-only; Retatrutide 18 human-only and 4 animal-only; Tesamorelin 14 human-only and 1 animal-only.
Calculated from goal liver-health; ledger date 2026-10-02; counts tirzepatide (human only 143, animal 15, rct 11), semaglutide (human only 305, animal 59, rct 29), kisspeptin (human only 0, animal 3, rct 0), bpc-157 (human only 3, animal 22, rct 0), retatrutide (human only 18, animal 4, rct 1), tesamorelin (human only 14, animal 1, rct 7). Formula: Copied from web/src/data/goals.json: peptides[].ledger.humanOnly.n and ledger.animal.n for this goal (PubMed title/abstract search, humans[mh] NOT animals vs animals NOT humans).
In the interim analysis of the phase 3 semaglutide trial in biopsy-defined MASH, steatohepatitis resolved without worsening of fibrosis in 62.9% on semaglutide versus 34.3% on placebo.[2]
In a phase 2 trial of people with biopsy-confirmed MASH, 44% on the lowest tirzepatide dose met the resolution criteria versus 10% on placebo.[1]
In a substudy of people with MASLD, the mean relative change in liver fat at 24 weeks was -82.4% with retatrutide 12 mg versus +0.3% with placebo. This is a fat measurement, not a biopsy outcome.[5]
In patients with HIV and fatty liver, tesamorelin reduced hepatic fat fraction more than placebo, with an absolute effect size of -4.1%.[6]
In mice with radiation-induced liver injury, BPC 157 reduced plasma AST and ALT and inhibited hydropic degeneration of the liver. This is animal data.[4]
What is FDA-labelled for this
Wegovy's label includes treatment of noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults.[8]
The same label lists acute pancreatitis as observed in patients treated with GLP-1 receptor agonists, including Wegovy.[8]
Common questions
Which peptide is best for fatty liver?
Semaglutide and tirzepatide each have a biopsy-based MASH trial cited on this page. In the tirzepatide phase 2 trial, resolution was 44% on 5 mg versus 10% on placebo.[1]
Does semaglutide reduce liver fibrosis?
In the same interim analysis, fibrosis was reduced without worsening steatohepatitis in 36.8% on semaglutide versus 22.4% on placebo.[2]
Did the earlier semaglutide trial show fibrosis improvement?
In the earlier semaglutide trial, an improvement in fibrosis stage occurred in 43% of the 0.4 mg group and 33% of the placebo group (P = 0.48).[9]
Explore nearby goals
Sources
- 1Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.The New England journal of medicine · 2024PMID 38856224Accessed 2 Oct 2026
- 2Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 3Kisspeptin Mitigates Hepatic De Novo Lipogenesis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Cells · 2025PMID 40862768Accessed 2 Oct 2026
- 4Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro.Life sciences · 2022PMID 36228773Accessed 2 Oct 2026
- 5Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nature medicine · 2024PMID 38858523Accessed 2 Oct 2026
- 6Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 7Official web pageOfficial web page · web page
- 8WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 9A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.The New England journal of medicine · 2021PMID 33185364Accessed 2 Oct 2026
Found an error? Report a correction.